BeOne Medicines
239 hedge funds and large institutions have $10.4B invested in BeOne Medicines in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 99 increasing their positions, 79 reducing their positions, and 43 closing their positions.
69% more call options, than puts
Call options by funds: $23.6M | Put options by funds: $14M
25% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 79
0.59% less ownership
Funds ownership: 54.2% → 53.61% (-0.59%)
9% less funds holding
Funds holding: 264 → 239 (-25)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
23% less capital inflows, than outflows
Capital inflows: $490M | Capital outflows: $635M
49% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$151M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$38.4M |
| 3 |
Bridgewater Associates
Westport,
Connecticut
|
+$32.8M |
| 4 |
Zeal Asset Management
Central,
Hong Kong
|
+$30.1M |
| 5 |
Capital International Inc
Los Angeles,
California
|
+$30M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$144M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$93.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$59.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$45M |
| 5 |
Indus Capital Partners
New York
|
-$28.8M |
ONC Hedge Fund Activity: Q1 2022 in Review
239 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q1 2022, worth a combined $10.4B — down 31% from $15B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of ONC and 22 opened new positions — a net loss of 21 holders — while 79 trimmed existing stakes and 99 added.
The largest buyer was Capital International Investors, adding an estimated $151M. The largest seller was Wellington Management Group, cutting an estimated $144M.
- 239 institutional investors held BeOne Medicines (ONC) as of Q1 2022, down from 264 in Q4 2021.
- Funds reported $10.4B of BeOne Medicines stock for Q1 2022, down 31% quarter-over-quarter.
- 22 funds opened new BeOne Medicines positions in Q1 2022 and 43 closed out, a net change of -21 holders.
- The largest BeOne Medicines buyer in Q1 2022 was Capital International Investors, an estimated $151M added.
- The largest BeOne Medicines seller in Q1 2022 was Wellington Management Group, an estimated $144M sold.
Based on aggregated 13F filings for Q1 2022.